I recently participated in a 'debate' with Anees Chagpar (moderated by David Brenin) on the pros and cons of using molecular assays for decision making regarding the benefit of XRT after breast conservation for DCIS. Prior to preparing for this webinar ...
Jennifer, I just looked up the Ask2Me website and it is a GREAT resource! I have not used this previously. In our high risk clinic, we have mostly been using NCCN and the input of our genetics counselors to determine risks based on non-BRCA mutations. ...
What is really impressive is the >20% 5 year OS in carefully selected patients with low volume disease that is completely resected This is about 10% less than what we see in colon cancer. Now that we have effective systemic chemotherapy we will likely ...